{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T16:24:52Z","timestamp":1794846292749,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cataract caused by crystallin aggregation is the leading cause of vision impairment and blindness globally. The only available treatment option so far is surgery. In this study, we leverage lipid nanoparticles (LNPs)-formulated mRNA encoding human lanosterol synthase (hLSS) to elevate lanosterol levels in the lens as a potential anti-cataract therapy. hLSS mRNA delivered with aromatized LNPs can be avidly taken up and translated into hLSS proteins in mammalian cells. mRNA formulations administered via intravitreal, subconjunctival, intracameral, or subretinal injection in rats display distinct kinetics and bio-distribution profiles, among which intracameral injection achieves sustained and selective protein expression in the lens. In comparison to clinically used LNPs, aromatized LNPs show more than seven-fold higher mRNA delivery potency in rats upon intracameral injection, without inducing significant ocular lesions. Furthermore, ocular delivery of hLSS mRNA-loaded formulations leads to elevated levels of hLSS proteins and lanosterol within the lens and a remarkable improvement in cataract symptoms in two rat models of cataract. Collectively, topical delivery of hLSS mRNA-LNPs to the eyes offers a potential strategy to reduce intracellular aggregation of crystallins and ameliorate cataract development.<\/jats:p>","DOI":"10.1038\/s41467-025-63553-5","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T12:29:34Z","timestamp":1758889774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Ocular delivery of lipid nanoparticles-formulated mRNA encoding lanosterol synthase ameliorates cataract in rats"],"prefix":"10.1038","volume":"16","author":[{"given":"Ruiteng","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8950-5966","authenticated-orcid":false,"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-8342","authenticated-orcid":false,"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2387-8305","authenticated-orcid":false,"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"63553_CR1","doi-asserted-by":"publisher","first-page":"15014","DOI":"10.1038\/nrdp.2015.14","volume":"1","author":"D Lam","year":"2015","unstructured":"Lam, D. et al. Cataract. Nat. Rev. Dis. Prim. 1, 15014 (2015).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"63553_CR2","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/S0140-6736(17)30544-5","volume":"390","author":"Y-C Liu","year":"2017","unstructured":"Liu, Y.-C., Wilkins, M., Kim, T., Malyugin, B. & Mehta, J. S. Cataracts.  Lancet 390, 600\u2013612 (2017).","journal-title":"Lancet"},{"key":"63553_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0140-6736(22)01839-6","volume":"401","author":"MV Cicinelli","year":"2023","unstructured":"Cicinelli, M. V., Buchan, J. C., Nicholson, M., Varadaraj, V. & Khanna, R. C. Cataracts. Lancet 401, 377\u2013389 (2023).","journal-title":"Lancet"},{"key":"63553_CR4","unstructured":"GBD 2019 Blindness and Vision Impairment Collaborators. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob. Health 9, e144\u2013e160 (2021)."},{"key":"63553_CR5","doi-asserted-by":"publisher","first-page":"e2105905","DOI":"10.1002\/advs.202105905","volume":"9","author":"C Yang","year":"2022","unstructured":"Yang, C. et al. Precise Detection of Cataracts with Specific High-Risk Factors by Layered Binary Co-Ionizers Assisted Aqueous Humor Metabolic Analysis. Adv. Sci. 9, e2105905 (2022).","journal-title":"Adv. Sci."},{"key":"63553_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.addr.2018.03.009","volume":"126","author":"TR Thrimawithana","year":"2018","unstructured":"Thrimawithana, T. R. et al. Drug delivery to the lens for the management of cataracts. Adv. Drug Deliv. Rev. 126, 185\u2013194 (2018).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"63553_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1021\/acs.accounts.0c00014","volume":"53","author":"KW Roskamp","year":"2020","unstructured":"Roskamp, K. W., Paulson, C. N., Brubaker, W. D. & Martin, R. W. Function and Aggregation in Structural Eye Lens Crystallins. Acc. Chem. Res. 53, 863\u2013874 (2020).","journal-title":"Acc. Chem. Res."},{"key":"63553_CR8","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nature14650","volume":"523","author":"L Zhao","year":"2015","unstructured":"Zhao, L. et al. Lanosterol reverses protein aggregation in cataracts. Nature 523, 607\u2013611 (2015).","journal-title":"Nature"},{"key":"63553_CR9","doi-asserted-by":"publisher","first-page":"10514","DOI":"10.1073\/pnas.1019152108","volume":"108","author":"P Das","year":"2011","unstructured":"Das, P., King, J. A. & Zhou, R. Aggregation of \u03b3-crystallins associated with human cataracts via domain swapping at the C-terminal \u03b2-strands. Proc. Natl. Acad. Sci. 108, 10514\u201310519 (2011).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"63553_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.molmed.2012.03.005","volume":"18","author":"KL Moreau","year":"2012","unstructured":"Moreau, K. L. & King, J. A. Protein misfolding and aggregation in cataract disease and prospects for prevention. Trends Mol. Med. 18, 273\u2013282 (2012).","journal-title":"Trends Mol. Med."},{"key":"63553_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22782-0","volume":"12","author":"S Shin","year":"2021","unstructured":"Shin, S. et al. Qki activates Srebp2-mediated cholesterol biosynthesis for maintenance of eye lens transparency. Nat. Commun. 12, 3005 (2021).","journal-title":"Nat. Commun."},{"key":"63553_CR12","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1194\/jlr.R004119","volume":"51","author":"D Borchman","year":"2010","unstructured":"Borchman, D. & Yappert, M. C. Lipids and the ocular lens. J. Lipid Res. 51, 2473\u20132488 (2010).","journal-title":"J. Lipid Res."},{"key":"63553_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1167\/iovs.64.15.12","volume":"64","author":"P Ma","year":"2023","unstructured":"Ma, P. et al. Lanosterol synthase prevents EMT during lens epithelial fibrosis via regulating SREBP1. Invest. Ophthalmol. Vis. Sci. 64, 12 (2023).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"63553_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1172\/JCI20797","volume":"116","author":"M Mori","year":"2006","unstructured":"Mori, M. et al. Lanosterol synthase mutations cause cholesterol deficiency\u2013associated cataracts in the Shumiya cataract rat.  J. Clin. Invest. 116, 395\u2013404 (2006).","journal-title":"J. Clin. Invest."},{"key":"63553_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.etp.2005.02.006","volume":"57","author":"J Funk","year":"2005","unstructured":"Funk, J. & Landes, C. Histopathologic findings after treatment with different oxidosqualene cyclase (OSC) inhibitors in hamsters and dogs. Exp. Toxicol. Pathol. 57, 29\u201338 (2005).","journal-title":"Exp. Toxicol. Pathol."},{"key":"63553_CR16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/019262301317052440","volume":"29","author":"IT Pyrah","year":"2001","unstructured":"Pyrah, I. T. et al. Toxicologic lesions associated with two related inhibitors of oxidosqualene cyclase in the dog and mouse. Toxicol. Pathol. 29, 174\u2013179 (2001).","journal-title":"Toxicol. Pathol."},{"key":"63553_CR17","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1126\/science.aac9145","volume":"350","author":"LN Makley","year":"2015","unstructured":"Makley, L. N. et al. Pharmacological chaperone for \u03b1-crystallin partially restores transparency in cataract models. Science 350, 674\u2013677 (2015).","journal-title":"Science"},{"key":"63553_CR18","doi-asserted-by":"publisher","first-page":"101112","DOI":"10.1016\/j.preteyeres.2022.101112","volume":"92","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. The lens epithelium as a major determinant in the development, maintenance, and regeneration of the crystalline lens. Prog. Retin. Eye Res. 92, 101112 (2023).","journal-title":"Prog. Retin. Eye Res."},{"key":"63553_CR19","doi-asserted-by":"publisher","first-page":"8479","DOI":"10.1021\/jacs.8b03065","volume":"140","author":"H Kang","year":"2018","unstructured":"Kang, H., Yang, Z. & Zhou, R. Lanosterol disrupts aggregation of human \u03b3D-Crystallin by Binding to the hydrophobic dimerization interface. J. Am. Chem. Soc. 140, 8479\u20138486 (2018).","journal-title":"J. Am. Chem. Soc."},{"key":"63553_CR20","doi-asserted-by":"publisher","first-page":"8693","DOI":"10.1021\/acs.jmedchem.8b00705","volume":"61","author":"X Yang","year":"2018","unstructured":"Yang, X. et al. Synthesis, evaluation, and structure-activity relationship study of lanosterol derivatives to reverse mutant-crystallin-induced protein aggregation. J. Med Chem. 61, 8693\u20138706 (2018).","journal-title":"J. Med Chem."},{"key":"63553_CR21","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1021\/acs.jced.9b00390","volume":"65","author":"K Li","year":"2020","unstructured":"Li, K. & Forciniti, D. Solubility of Lanosterol in organic solvents and in water\u2013alcohol mixtures at 101.8\u2009kPa. J. Chem. Eng. Data 65, 436\u2013445 (2020).","journal-title":"J. Chem. Eng. Data"},{"key":"63553_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/13816810.2016.1214971","volume":"38","author":"C Skinner","year":"2017","unstructured":"Skinner, C. & Miraldi Utz, V. Pharmacological approaches to restoring lens transparency: Real world applications. Ophthalmic Genet. 38, 201\u2013205 (2017).","journal-title":"Ophthalmic Genet."},{"key":"63553_CR23","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin, U., Kariko, K. & Tureci, O. mRNA-based therapeutics-developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759\u2013780 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"63553_CR24","doi-asserted-by":"publisher","first-page":"e1530","DOI":"10.1002\/wnan.1530","volume":"11","author":"B Li","year":"2019","unstructured":"Li, B., Zhang, X. & Dong, Y. Nanoscale platforms for messenger RNA delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 11, e1530 (2019).","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"63553_CR25","doi-asserted-by":"publisher","first-page":"2200082","DOI":"10.1002\/anbr.202200082","volume":"2","author":"Z Liu","year":"2022","unstructured":"Liu, Z., Li, Z. & Li, B. Nonviral Delivery of CRISPR\/Cas Systems in mRNA Format. Adv. NanoBiomed. Res. 2, 2200082 (2022).","journal-title":"Adv. NanoBiomed. Res."},{"key":"63553_CR26","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","volume":"40","author":"E Rohner","year":"2022","unstructured":"Rohner, E., Yang, R., Foo, K. S., Goedel, A. & Chien, K. R. Unlocking the promise of mRNA therapeutics. Nat. Biotechnol. 40, 1586\u20131600 (2022).","journal-title":"Nat. Biotechnol."},{"key":"63553_CR27","doi-asserted-by":"crossref","unstructured":"Huang, X. et al. The landscape of mRNA nanomedicine. Nat. Med. 28, 2273\u20132287 (2022).","DOI":"10.1038\/s41591-022-02061-1"},{"key":"63553_CR28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.tibtech.2023.08.005","volume":"42","author":"J Wu","year":"2024","unstructured":"Wu, J., Wu, W., Zhou, B. & Li, B. Chimeric antigen receptor therapy meets mRNA technology. Trends Biotechnol. 42, 228\u2013240 (2024).","journal-title":"Trends Biotechnol."},{"key":"63553_CR29","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","volume":"23","author":"PR Cullis","year":"2024","unstructured":"Cullis, P. R. & Felgner, P. L. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat. Rev. Drug Discov. 23, 709\u2013722 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"63553_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41573-023-00827-x","volume":"23","author":"M Metkar","year":"2024","unstructured":"Metkar, M., Pepin, C. S. & Moore, M. J. Tailor made: the art of therapeutic mRNA design. Nat. Rev. Drug Discov. 23, 67\u201383 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"63553_CR31","doi-asserted-by":"publisher","first-page":"e2101707","DOI":"10.1002\/adma.202101707","volume":"33","author":"M Li","year":"2021","unstructured":"Li, M. et al. Secreted Expression of mRNA-encoded truncated ACE2 variants for SARS-CoV-2 via lipid-like nanoassemblies. Adv. Mater. 33, e2101707 (2021).","journal-title":"Adv. Mater."},{"key":"63553_CR32","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1021\/acs.bioconjchem.6b00090","volume":"27","author":"B Li","year":"2016","unstructured":"Li, B., Luo, X. & Dong, Y. Effects of chemically modified messenger RNA on Protein Expression. Bioconjug. Chem. 27, 849\u2013853 (2016).","journal-title":"Bioconjug. Chem."},{"key":"63553_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00232-007-9019-y","volume":"216","author":"RT Mathias","year":"2007","unstructured":"Mathias, R. T., Kistler, J. & Donaldson, P. The lens circulation. J. Membr. Biol. 216, 1\u201316 (2007).","journal-title":"J. Membr. Biol."},{"key":"63553_CR34","doi-asserted-by":"publisher","first-page":"101152","DOI":"10.1016\/j.preteyeres.2022.101152","volume":"95","author":"PJ Donaldson","year":"2023","unstructured":"Donaldson, P. J., Chen, Y., Petrova, R. S., Grey, A. C. & Lim, J. C. Regulation of lens water content: Effects on the physiological optics of the lens. Prog. Retin. Eye Res. 95, 101152 (2023).","journal-title":"Prog. Retin. Eye Res."},{"key":"63553_CR35","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/eye.1999.114","volume":"13","author":"J Horwitz","year":"1999","unstructured":"Horwitz, J., Bova, M. P., Ding, L. L., Haley, D. A. & Stewart, P. L. Lens alpha-crystallin: function and structure. Eye 13, 403\u2013408 (1999).","journal-title":"Eye"},{"key":"63553_CR36","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/d41586-021-00888-1","volume":"592","author":"P Boya","year":"2021","unstructured":"Boya, P. Lipid dismantling of lens organelles for clear vision. Nature 592, 509\u2013510 (2021).","journal-title":"Nature"},{"key":"63553_CR37","doi-asserted-by":"publisher","first-page":"pbac021","DOI":"10.1093\/pcmedi\/pbac021","volume":"5","author":"K Zhang","year":"2022","unstructured":"Zhang, K. et al. Inhibitory effect of lanosterol on cataractous lens of cynomolgus monkeys using a subconjunctival drug release system. Precis. Clin. Med. 5, pbac021 (2022).","journal-title":"Precis. Clin. Med."},{"key":"63553_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-44676-4","volume":"9","author":"DM Daszynski","year":"2019","unstructured":"Daszynski, D. M. et al. Failure of Oxysterols such as Lanosterol to restore lens clarity from cataracts. Sci. Rep. 9, 8459 (2019).","journal-title":"Sci. Rep."},{"key":"63553_CR39","doi-asserted-by":"publisher","first-page":"888","DOI":"10.4103\/0301-4738.176040","volume":"63","author":"PM Shanmugam","year":"2015","unstructured":"Shanmugam, P. M. et al. Effect of lanosterol on human cataract nucleus. Indian J. Ophthalmol. 63, 888\u2013890 (2015).","journal-title":"Indian J. Ophthalmol."},{"key":"63553_CR40","doi-asserted-by":"publisher","first-page":"1231521","DOI":"10.3389\/fgene.2024.1231521","volume":"15","author":"M Hashimi","year":"2024","unstructured":"Hashimi, M., Amin, H. A., Zagkos, L., Day, A. C. & Drenos, F. Using genetics to investigate the association between lanosterol and cataract. Front Genet.\u00a015, 1231521 (2024).","journal-title":"Front Genet."},{"key":"63553_CR41","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Aguado, I. et al. mRNA-based nanomedicinal products to address corneal inflammation by interleukin-10 supplementation. Pharmaceutics 13, 1472 (2021).","DOI":"10.3390\/pharmaceutics13091472"},{"key":"63553_CR42","doi-asserted-by":"crossref","unstructured":"O\u2019Hare, M. et al. An mRNA-encoded dominant-negative inhibitor of transcription factor RUNX1 suppresses vitreoretinal disease in experimental models. Sci. Transl. Med. 16, eadh0994 (2024).","DOI":"10.1126\/scitranslmed.adh0994"},{"key":"63553_CR43","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.tibtech.2024.05.002","volume":"42","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Ocular RNA nanomedicine: engineered delivery nanoplatforms in treating eye diseases. Trends Biotechnol. 42, 1439\u20131452 (2024).","journal-title":"Trends Biotechnol."},{"key":"63553_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59501-y","volume":"16","author":"Z Liu","year":"2025","unstructured":"Liu, Z. et al. Structure-guided design of endosomolytic chloroquine-like lipid nanoparticles for mRNA delivery and genome editing. Nat. Commun. 16, 4241 (2025).","journal-title":"Nat. Commun."},{"key":"63553_CR45","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.exer.2007.10.016","volume":"86","author":"M Sakthivel","year":"2008","unstructured":"Sakthivel, M. et al. Prevention of selenite-induced cataractogenesis in Wistar rats by the polyphenol, ellagic acid. Exp. Eye Res. 86, 251\u2013259 (2008).","journal-title":"Exp. Eye Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63553-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63553-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63553-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T13:04:52Z","timestamp":1758891892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63553-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["63553"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-63553-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B. Li, R. Song, Y. Lin, and Z. Liu are listed as inventors on a patent application describing the use of lipid nanoparticles as a platform for hLSS mRNA delivery and cataract treatment. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8522"}}